Tvardi Therapeutics, Incorporated   Report issue

For profit Phase 2
Founded: Houston TX United States (2017)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2017
NCT03195699
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Tvardi Therapeutics, Inc | Tvardi Therapeutics, Incorporated

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Liver Neoplasms (Phase 1)

Neoplasms (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 5